Acute promyelocytic leukemia presenting with basophilia: diagnostic features and clinical observation
https://doi.org/10.17650/2782-3202-2024-4-2-65-70
Abstract
Acute promyelocytic leukemia (APL) is a blood tumor characterized by aggressive clinical progression with characteristic clinical and laboratory signs (typical tumor cell morphology, severe hemorrhagic syndrome, hemorrhages with hematoma formation, excessive fibrinolysis, disseminated intravascular coagulation syndrome) but modern approaches to therapy potentially make this disease fully curable. APL is considered one of the most studied subtypes of acute leukemia and is characterized by abnormal proliferation of promyelocytes in the bone marrow. The morphologic picture of APL is quite diverse, but an increased basophil count represents a rare manifestation that requires further study and understanding of its significance. Currently, there are limited scientific data on the clinical course and response to standard therapy in patients with APL presenting with basophilia.
About the Authors
K. A. AkezhevaRussian Federation
Karina A. Akezheva
4 Novy Zykovskiy Proezd, Moscow 125167
O. A. Aleshina
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
A. N. Vasileva
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
V. N. Dvirnyk
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
A. A. Ershov
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
T. N. Obukhova
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
A. M. Kovrigin
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
V. V. Troitskaya
Russian Federation
4 Novy Zykovskiy Proezd, Moscow 125167
References
1. Hillestad L.K. Acute promyelocytic leukemia. Acta Med Scand 1957; 159(3):189–94.
2. Lo-Coco F., Hasan S.K. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2014;27(1):3–9. DOI: 10.1016/j.beha.2014.04.006
3. Mannan A., Muhsen I.N., Barragán E. et al. Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants. Hematol Oncol Stem Cell Ther 2020;13(4):189–201. DOI: 10.1016/j.hemonc.2020.05.007
4. Lo-Coco F., Di Donato L., GIMEMA, Schlenk R.F. Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med 2016;374(12):1197–8. DOI: 10.1056/NEJMc1513710
5. Salhotra A., Mei M. Acute promyelocytic leukemia: update on risk stratification and treatment practices. Cancer Treat Res 2021;181:45–55. DOI: 10.1007/978-3-030-78311-2_3
6. Acute promyelocytic leukemia. Clinical recommendations of the Ministry of Health Russia. 2020. Available at: https://cr.minzdrav.gov.ru/schema/132_1?ysclid=lwgbknpntg696196868
7. Rieu J.B., Canali A., Thene E. et al. Acute promyelocytic leukaemia associated with atypical basophilia. Br J Haematol 2023;201(6):1017. DOI: 10.1111/bjh.18793
8. Tallman M.S., Hakimian D., Snower D. et al. Basophilic differentiation in acute promyelocytic leukemia. Leukemia 1993;7(4):521–6.
9. Kahn P., Plementas H. [Case of basophilic promyelocytic-I-leukemia (In German)]. Wien Z Inn Med 1971;52(12):578–583.
10. Matarraz S., Leoz P., Fernández C. et al. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Mod Pathol 2018;31(8):1318–31. DOI: 10.1038/s41379-018-0038-2
Review
For citations:
Akezheva K.A., Aleshina O.A., Vasileva A.N., Dvirnyk V.N., Ershov A.A., Obukhova T.N., Kovrigin A.M., Troitskaya V.V. Acute promyelocytic leukemia presenting with basophilia: diagnostic features and clinical observation. MD-Onco. 2024;4(2):65-70. (In Russ.) https://doi.org/10.17650/2782-3202-2024-4-2-65-70